Informed Burn-In Decisions in RAR: Harmonizing Adaptivity and Inferential Precision Based on Study Setting

TL;DR

This paper introduces a systematic framework for determining the optimal burn-in period in Response-Adaptive Randomization, balancing statistical integrity and adaptive benefits based on study-specific factors.

Contribution

It presents the first principled formula for burn-in length that incorporates sample size, problem difficulty, reactivity, and allocation error.

Findings

The formula effectively stabilizes trials in simulations.

It reduces type-I error inflation and estimation bias.

It maintains power and patient benefit advantages.

Abstract

Response-Adaptive Randomization (RAR) is recognized for its potential to deliver improvements in patient benefit. However, the utility of RAR is contingent on regularization methods to mitigate early instability and preserve statistical integrity. A standard regularization approach is the ''burn-in'' period, an initial phase of equal randomization before treatment allocation adapts based on accrued data. The length of this burn-in is a critical design parameter, yet its selection remains unsystematic and improvised, as no established guideline exists. A poorly chosen length poses significant risks: one that is too short leads to high estimation bias and type-I error rate inflation, while one that is too long impedes the intended patient and power benefits of using adaptation. The challenge of selecting the burn-in generalizes to a fundamental question: what is the statistically appropriate timing for the first adaptation? We introduce the first systematic framework for determining burn-in length. This framework synthesizes core factors - total sample size, problem difficulty, and two novel metrics (reactivity and expected final allocation error) - into a single, principled formula. Simulation studies, grounded in real-world designs, demonstrate that lengths derived from our formula successfully stabilize the trial. The formula identifies a ''sweet spot'' that mitigates type-I error rate inflation and mean-squared error, preserving the advantages of higher power and patient benefit. This framework moves researchers from conjecture toward a systematic, reliable approach.